Search
for
Sort by
Research 31–60 of 136
- Oral Tofacitinib for the Management of Moderate to Severe Alopecia Areata in Children and Adolescents: A Retrospective Study of 36 Patients
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- Ivarmacitinib stimulates hair regrowth in severe alopecia areata
- Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-center retrospective study
- Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
- Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials
- Alopecia universalis. Partial response to tofacitinib
- Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
- Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study
- Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
- Systemic treatments for alopecia areata: A systematic review
- Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
- Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of the Literature
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy
- Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
- STRIAA (Severity TRichoscopy Index Alopecia Areata): Validation of a Novel Trichoscopic Tool for Evaluation of Alopecia Areata
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
- Retrospective Analysis of Oral Tofacitinib Treatment for Alopecia Areata at a Tertiary Care Hospital in Saudi Arabia
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata